Keytruda (pembrolizumab)

Triple-negative breast cancer (TNBC), locally recurrent unresectable or metastatic, in adult patients who have not received prior chemotherapy for metastatic disease and whose tumors express PD‐L1 (CPS ≥ 10) as determined by a validated test (in combination with chemotherapy)